Clinical Trials
543
72 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1893
Active, not recruiting
39
7.2%
Completed
271
49.9%
Enrolling By Invitation
3
0.6%
Not yet recruiting
30
5.5%
Recruiting
90
16.6%
Suspended
1
0.2%
Terminated
52
9.6%
Unknown
6
1.1%
Withdrawn
51
9.4%
No approval data available
- Pattern Computer and the Medical College of Wisconsin published initial results for a rapid, point-of-care tier-1 cancer screening test using saliva transmission hyperspectral spectroscopy paired with machine learning. - The ProSpectral device scanned just two drops of saliva in approximately 3 seconds, supporting sub-minute time-to-results with no reagent costs, versus a two-week turnaround for sequencing-based cfDNA blood assays. - Across a 251-participant cohort, the model achieved 91% specificity, 44% sensitivity, 61% balanced accuracy, and an F1-score of 0.55, with statistical saturation analysis suggesting specificity above 98% is attainable with fewer than 500 samples. - The study, led by Razelle Kurzrock, MD, was presented at ASCO, published in the Journal of Clinical Oncology, and showcased as a poster at the ADLM annual meeting.
- Kratom-related reports to U.S. poison centers rose from 19 in 2010 to 1,242 in 2023, with severe outcomes climbing from zero to 158 over the same period. - An analysis of 8,919 exposures found roughly 13% met the severe-outcome threshold, and 34% of all exposures resulted in hospital admission. - States without any kratom regulation recorded significantly higher rates of exposure, severe outcomes, hospitalization, and overall healthcare use compared with states that ban kratom. - Federal regulators have moved to restrict high-potency semisynthetic 7-hydroxymitragynine (7-OH) products, which act far more powerfully on opioid receptors than leaf kratom.
- Elekta's Evo CT-Linac system received FDA 510(k) clearance, enabling U.S. radiation oncology professionals to access integrated high-quality CT imaging with linear accelerator functionality. - The system features Iris, an AI-enhanced imaging capability that provides clearer visualization of tumors and organs-at-risk compared to traditional cone-beam CT imaging. - FDA approval positions Elekta to expand its U.S. market presence in the $8.64 billion radiation therapy market, which is expected to grow at 9% CAGR through 2035.
- The DART trial (NCI/SWOG S1609) represents the largest immunotherapy study in rare cancer patients, demonstrating that combination nivolumab plus ipilimumab maintains efficacy regardless of prior anti-PD-1/PD-L1 exposure. - Brain metastases patients showed comparable safety and activity profiles with the combination immunotherapy, challenging the common practice of excluding these patients from clinical trials. - The multicenter basket trial provides crucial evidence that rare cancer patients with brain metastases need and can benefit from immunotherapy treatment options.
- Ryght AI announces formation of inaugural Scientific Advisory Board comprising 12 globally recognized experts in oncology, hematology, dermatology, and AI to guide clinical trial innovation. - The board will oversee development of AI Site Twin technology, which creates dynamic digital replicas of research facilities to transform site selection and trial operations. - Advisory board members emphasize the platform's potential to accelerate patient recruitment and streamline workflows, bringing therapies to market months or years ahead of schedule. - The technology addresses longstanding challenges in clinical trial feasibility by replacing static, outdated data with real-time insights powered by generative AI.
- Hansa Biopharma announced encouraging topline results from its pivotal U.S. Phase III ConfIdeS trial, marking a significant milestone for the company's IgG-cleaving enzyme therapy. - The trial results represent a potential breakthrough for highly sensitized kidney transplant patients who currently have limited treatment options beyond dialysis. - The company's leadership, including CEO Renee Aguiar-Lucander and Chief Medical Officer Richard Philipson, expressed pride in delivering these positive outcomes for patients with significant unmet medical needs. - The results were presented during a dedicated conference call featuring distinguished transplant experts from NYU Langone Transplant Institute and Medical College of Wisconsin.
- The BOSTON trial demonstrated that selinexor, bortezomib, and dexamethasone (SVd) combination achieved a median progression-free survival of 29.5 months in proteasome inhibitor-naive patients, compared to 9.7 months with bortezomib/dexamethasone alone. - The SVd regimen showed significant overall survival benefit with a hazard ratio of 0.54 in PI-naive patients, representing a substantial improvement over standard therapy. - Despite higher rates of cytopenia and gastrointestinal events, the adverse event profile was manageable with once-weekly dosing and supportive care measures. - The once-weekly administration schedule for both selinexor and bortezomib in 35-day cycles offers improved quality of life compared to traditional twice-weekly regimens.
- Measurable residual disease (MRD) testing could enhance value-based care in multiple myeloma by enabling personalized treatment decisions, including tailored maintenance therapy and avoiding overtreatment in patients with deep responses. - Clinical trials such as MASTER, MIDAS, PERSEUS, and GRIFFIN serve as models for risk-adapted consolidation and maintenance decisions using MRD testing to guide treatment strategies. - Significant barriers to routine MRD implementation include high costs, particularly for next-generation sequencing, lack of standardized protocols, and inconsistent insurance coverage for repeated testing. - Academic centers have better access to MRD testing through clinical trials and manufacturer support, while community practices face greater challenges limiting widespread adoption until costs decrease and testing becomes standardized.
- Oncologists commonly target 2 years of immunotherapy treatment in advanced NSCLC before considering discontinuation, based on evidence showing many patients maintain durable responses after stopping treatment. - Circulating tumor DNA testing is increasingly used to assess minimal residual disease and guide treatment decisions at the 2-year mark through shared decision-making with patients. - Financial toxicity from expensive immunotherapy infusions is emerging as an important consideration alongside clinical outcomes, though it remains understudied compared to other adverse events. - Patients who discontinue immunotherapy after 2 years can avoid late-onset immune-related adverse events while potentially maintaining disease control, though some may experience relapse requiring retreatment.
- The PKIDS trial, the largest comparative effectiveness study of surgical interventions for pediatric kidney stones, enrolled 1,142 patients across 31 medical centers in the US and Canada. - Shockwave lithotripsy demonstrated equivalent stone clearance rates to ureteroscopy but with significantly better patient-reported outcomes including less pain and fewer urinary symptoms. - For kidney stones larger than 15 mm, percutaneous nephrolithotomy achieved superior stone clearance rates (94% vs 55%) compared to ureteroscopy with better recovery experiences. - The findings challenge current clinical practice where most children receive ureteroscopy despite uncertainty about optimal treatment approaches and patient impact.
